Future research in fertility-sparing management of early-stage endometrial cancer should prioritize biomarker-driven, stratified RCTs that integrate molecular subtyping (POLE, MMRd, p53-abn, NSMP) with validated predictors such as PR expression and early Ki-67 suppression [81,88]. This evidence concerns the gene POLE and endometrial cancer.